Currently, there are 183.65M common shares owned by the public and among those 181.14M shares have been available to trade.
The company’s stock has a 5-day price change of 9.65% and 6.64% over the past three months. LEGN shares are trading 3.69% year to date (YTD), with the 12-month market performance down to -36.24% lower. It has a 12-month low price of $29.27 and touched a high of $60.87 over the same period. LEGN has an average intraday trading volume of 1.23 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.04%, -4.73%, and -21.61% respectively.
Institutional ownership of Legend Biotech Corp ADR (NASDAQ: LEGN) shares accounts for 53.58% of the company’s 183.65M shares outstanding.
It has a market capitalization of $6.20B and a beta (3y monthly) value of 0.23. The earnings-per-share (ttm) stands at -$0.97. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.40% over the week and 5.06% over the month.
Earnings per share for the fiscal year are expected to increase by 18.06%, and 232.90% over the next financial year.
Looking at the support for the LEGN, a number of firms have released research notes about the stock. Redburn Atlantic stated their Buy rating for the stock in a research note on October 08, 2024, with the firm’s price target at $86. Truist coverage for the Legend Biotech Corp ADR (LEGN) stock in a research note released on June 17, 2024 offered a Buy rating with a price target of $88. H.C. Wainwright was of a view on May 24, 2024 that the stock is Buy, while Deutsche Bank gave the stock Buy rating on May 23, 2024, issuing a price target of $60. Scotiabank on their part issued Sector Outperform rating on April 17, 2024.
